Concurrent	 O
[P1]	 O
chemoradiotherapy	 O
[P2]	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
MDXiangnanQiu	 O

Concurrent	 O
chemoradiotherapy	 O
with	 O
[P1]	 O
raltitrexed	 O
[P2]	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
MDXiangnanQiu	 O

Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
MDXiangnanQiu	 O

Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
Concurrent	 O
[P1]	 O
chemoradiotherapy	 O
[P2]	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
MDXiangnanQiu	 O

Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
[P1]	 O
raltitrexed	 O
[P2]	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
MDXiangnanQiu	 O

Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
MDXiangnanQiu	 O

PR	 O
China	 O
210002	 O
Nanjing	 O
PR	 O
China	 O
Concurrent	 O
[P1]	 O
chemoradiotherapy	 O
[P2]	 O
with	 O
raltitrexed	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
10.1097	 O
/	 O
MD.0000000000018732	 O
Received	 O
:	 O
17	 O
September	 O
2019	 O
/	 O
Received	 O
in	 O
final	 O
form	 O
:	 O
5	 O
December	 O
2019	 O
/	 O
Accepted	 O
:	 O
11	 O
December	 O
2019	 O

PR	 O
China	 O
210002	 O
Nanjing	 O
PR	 O
China	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
[P1]	 O
raltitrexed	 O
[P2]	 O
and	 O
nedaplatin	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
10.1097	 O
/	 O
MD.0000000000018732	 O
Received	 O
:	 O
17	 O
September	 O
2019	 O
/	 O
Received	 O
in	 O
final	 O
form	 O
:	 O
5	 O
December	 O
2019	 O
/	 O
Accepted	 O
:	 O
11	 O
December	 O
2019	 O

PR	 O
China	 O
210002	 O
Nanjing	 O
PR	 O
China	 O
Concurrent	 O
chemoradiotherapy	 O
with	 O
raltitrexed	 O
and	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
regimen	 O
for	 O
esophageal	 O
squamous	 O
cell	 O
carcinoma	 O
10.1097	 O
/	 O
MD.0000000000018732	 O
Received	 O
:	 O
17	 O
September	 O
2019	 O
/	 O
Received	 O
in	 O
final	 O
form	 O
:	 O
5	 O
December	 O
2019	 O
/	 O
Accepted	 O
:	 O
11	 O
December	 O
2019	 O

Intensity	 O
-	 O
modulated	 O
[P1]	 O
radiation	 O
therapy	 O
[P2]	 O
with	 O
a	 O
6-MV	 O
X	 O
-	 O
ray	 O
was	 O
used	 O
to	 O
deliver	 O
a	 O
total	 O
dose	 O
of	 O
60	 B-DOSAGE
Gy	 I-DOSAGE
(	 I-DOSAGE
1.8	 I-DOSAGE
-	 I-DOSAGE
2.0	 I-DOSAGE
Gy	 I-DOSAGE
per	 I-DOSAGE
fraction	 I-DOSAGE
)	 I-DOSAGE
to	 O
the	 O
primary	 O
tumor	 O
and	 O
50	 B-DOSAGE
Gy	 I-DOSAGE
to	 O
the	 O
subclinical	 O
region	 O
.	 O

Chemotherapy	 O
consisted	 O
of	 O
3	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
[P1]	 O
raltitrexed	 O
[P2]	 O
given	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
22	 I-DOSAGE
combined	 O
with	 O
80	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
nedaplatin	 O
given	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
to	 I-DOSAGE
3	 I-DOSAGE
and	 I-DOSAGE
22	 I-DOSAGE
to	 I-DOSAGE
24	 I-DOSAGE
.	 O

Chemotherapy	 O
consisted	 O
of	 O
3	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
raltitrexed	 O
given	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
22	 I-DOSAGE
[P1]	 O
combined	 O
with	 O
[P2]	 O
80	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
nedaplatin	 O
given	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
to	 I-DOSAGE
3	 I-DOSAGE
and	 I-DOSAGE
22	 I-DOSAGE
to	 I-DOSAGE
24	 I-DOSAGE
.	 O

Chemotherapy	 O
consisted	 O
of	 O
3	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
raltitrexed	 O
given	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
and	 I-DOSAGE
22	 I-DOSAGE
combined	 O
with	 O
80	 B-DOSAGE
mg	 I-DOSAGE
/	 I-DOSAGE
m	 I-DOSAGE
2	 I-DOSAGE
[P1]	 O
nedaplatin	 O
[P2]	 O
given	 O
on	 B-DOSAGE
days	 I-DOSAGE
1	 I-DOSAGE
to	 I-DOSAGE
3	 I-DOSAGE
and	 I-DOSAGE
22	 I-DOSAGE
to	 I-DOSAGE
24	 I-DOSAGE
.	 O

The	 O
chemotherapy	 O
dose	 O
was	 O
reduced	 O
by	 O
20	 O
%	 O
in	 O
the	 O
subsequent	 O
cycle	 O
if	 O
grade	 O
4	 O
myelotoxicity	 O
or	 O
grade	 O
â‰¥3	 O
non	 O
-	 O
myelotoxicity	 O
toxicity	 O
occurred	 O
,	 O
and	 O
chemotherapy	 O
and	 O
[P1]	 O
radiotherapy	 O
[P2]	 O
were	 O
suspended	 O
until	 O
bone	 O
marrow	 O
/	 O
other	 O
organ	 O
functions	 O
normalized	 O
.	 O

29	 O
patients	 O
completed	 O
the	 O
[P1]	 O
radiotherapy	 O
[P2]	 O
with	 O
median	 B-DOSAGE
dose	 I-DOSAGE
was	 I-DOSAGE
60	 I-DOSAGE
Gy	 I-DOSAGE
,	 O
1	 O
patients	 O
had	 O
interruption	 O
of	 O
treatment	 O
when	 O
received	 O
36	 O
Gy	 O
due	 O
to	 O
esophageal	 O
fistula	 O
.	 O

The	 O
second	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
dose	 O
was	 O
reduced	 O
by	 O
25	 O
%	 O
in	 O
two	 O
patient	 O
due	 O
to	 O
grade	 O
4	 O
myelotoxicity	 O
occurred	 O
.	 O

One	 O
patients	 O
developed	 O
esophageal	 O
fistula	 O
at	 O
a	 O
[P1]	 O
radiation	 O
[P2]	 O
dose	 O
of	 O
36	 O
Gy	 O
with	 O
1	 O
cycle	 O
concurrent	 O
raltitrexed	 O
/	 O
nedaplatin	 O
chemotherapy	 O
.	 O

One	 O
patients	 O
developed	 O
esophageal	 O
fistula	 O
at	 O
a	 O
radiation	 O
dose	 O
of	 O
36	 O
Gy	 O
with	 O
1	 O
cycle	 O
concurrent	 O
[P1]	 O
raltitrexed	 O
[P2]	 O
/	 O
nedaplatin	 O
chemotherapy	 O
.	 O

One	 O
patients	 O
developed	 O
esophageal	 O
fistula	 O
at	 O
a	 O
radiation	 O
dose	 O
of	 O
36	 O
Gy	 O
with	 O
1	 O
cycle	 O
concurrent	 O
raltitrexed	 O
/	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
chemotherapy	 O
.	 O

A	 O
possible	 O
explanation	 O
was	 O
the	 O
differences	 O
in	 O
[P1]	 O
radiation	 O
[P2]	 O
dose	 O
,	 O
radiation	 O
volume	 O
and	 O
chemotherapy	 O
regimens	 O
.	 O

The	 O
[P1]	 O
radiation	 O
[P2]	 O
dose	 O
of	 O
our	 O
study	 O
was	 O
lower	 O
than	 O
that	 O
of	 O
Zhu	 O
's	 O
study	 O
,	 O
with	 O
a	 O
median	 B-DOSAGE
dose	 I-DOSAGE
of	 I-DOSAGE
60	 I-DOSAGE
Gy	 I-DOSAGE
vs	 I-DOSAGE
64	 I-DOSAGE
Gy	 I-DOSAGE
(	 O
range	 O
,	 O
60	 O
-	 O
66	 O
Gy	 O
)	 O
.	 O

In	 O
conclusion	 O
,	 O
the	 O
present	 O
study	 O
suggests	 O
that	 O
CCRT	 O
with	 O
[P1]	 O
raltitrexed	 O
[P2]	 O
and	 O
nedaplatin	 O
agents	 O
frequently	 O
caused	 O
myelosuppression	 O
but	 O
was	 O
highly	 O
active	 O
and	 O
suggested	 O
to	 O
be	 O
a	 O
promising	 O
treatment	 O
option	 O
for	 O
locally	 O
advanced	 O
ESCC	 O
.	 O

In	 O
conclusion	 O
,	 O
the	 O
present	 O
study	 O
suggests	 O
that	 O
CCRT	 O
with	 O
raltitrexed	 O
and	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
agents	 O
frequently	 O
caused	 O
myelosuppression	 O
but	 O
was	 O
highly	 O
active	 O
and	 O
suggested	 O
to	 O
be	 O
a	 O
promising	 O
treatment	 O
option	 O
for	 O
locally	 O
advanced	 O
ESCC	 O
.	 O

These	 O
results	 O
suggest	 O
[P1]	 O
raltitrexed	 O
[P2]	 O
/	 O
nedaplatin	 O
could	 O
be	 O
used	 O
as	 O
an	 O
alternative	 O
for	 O
cisplatin/5-FU	 O
in	 O
CCRT	 O
for	 O
EC	 O
patients	 O
which	 O
should	 O
be	 O
further	 O
evaluated	 O
.	 O

These	 O
results	 O
suggest	 O
raltitrexed	 O
/	 O
[P1]	 O
nedaplatin	 O
[P2]	 O
could	 O
be	 O
used	 O
as	 O
an	 O
alternative	 O
for	 O
cisplatin/5-FU	 O
in	 O
CCRT	 O
for	 O
EC	 O
patients	 O
which	 O
should	 O
be	 O
further	 O
evaluated	 O
.	 O